PDF herunterladen
Planta Med 2017; 83(12/13): 977-984
DOI: 10.1055/s-0043-105390
Reviews
Georg Thieme Verlag KG Stuttgart · New York

New Knowledge About Old Drugs: The Anti-Inflammatory Properties of Cardiac Glycosides[*]

Robert Fürst
Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main
,
Ilse Zündorf
Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main
,
Theo Dingermann
Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 27. Januar 2017
revised 20. Februar 2017

accepted 02. März 2017

Publikationsdatum:
15. März 2017 (online)

   Lizenzen und Reprints

Abstract

In the 19th century, cardio-active steroid glycosides, shortly cardiac glycosides, were scientifically established as drugs against heart failure. Their in vivo, cellular, and molecular actions as well as their predominant target, Na+-K+-ATPase, have been comprehensively investigated in the 20th century and the discovery of endogenous cardiac glycosides has fostered this research field. In the last years, however, results from clinical trials and meta-analyses have questioned their therapeutic value due to efficacy and safety issues. This has led to a considerable decline of their usage. Beyond the cardiovascular system, cardiac glycosides have been increasingly recognized as antitumor compounds and Na+-K+-ATPase has evolved into a promising drug target in oncology. A wealth of review articles exists that intensively discuss these topics. Surprisingly, the anti-inflammatory actions of cardiac glycosides, which were discovered in the 1960s, have so far hardly been perceived and have not yet been summarized. This review provides an overview of the in vivo and in vitro actions of cardiac glycosides on inflammatory processes and of the signaling mechanisms responsible for these effects: cardiac glycosides have been found to decrease inflammatory symptoms in different animal models of acute and chronic inflammation. Regarding the underlying mechanisms most research has focused on leukocytes. In these cells, cardiac glycosides primarily inhibit cell proliferation and the secretion of proinflammatory cytokines.

Key words

cardiac glycosides - ouabain - inflammation - animal models - molecular mechanisms

* Part of the special issue dedicated to Professor Max Wichtl.


 

  • References

  • 1 Greeff K, Schadewaldt H. Introduction and Remarks on the History of cardiac Glycosides. In: Greeff K. ed. Cardiac Glycosides. Berlin, Heidelberg: Springer; 1981: 1-12
    Google Scholar
  • 2 Lampe D, Lampe H, Berwing K, Parsi RA, Mai I. On the problem of optimum digitlaization in man. Int J Clin Pharmacol Biopharm 1978; 16: 380-383
    PubMedGoogle Scholar
  • 3 Regal W, Nanut M. Von der Geheimrezeptur zum Herzglykosid. Available at. http://www.springermedizin.at/artikel/2184-von-der-geheimrezeptur-zum-herzglykosid Accessed January 5, 2017
    PubMedGoogle Scholar
  • 4 Repke K, Portius HJ. Comparison of the effect of steroid lactones on the transport-ATPase and ion transport of erythrocytes. Folia Haematol Int Mag Klin Morphol Blutforsch 1965; 83: 108-118
    PubMedGoogle Scholar
  • 5 Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80: 65-77
    CrossrefPubMedGoogle Scholar
  • 6 Haddy FJ. Endogenous digitalis-like factor or factors. N Engl J Med 1987; 316: 621-623
    CrossrefPubMedGoogle Scholar
  • 7 Poston L. Endogenous sodium pump inhibitors: a role in essential hypertension?. Clin Sci (Lond) 1987; 72: 647-655
    CrossrefPubMedGoogle Scholar
  • 8 Haber E, Haupert jr. GT. The search for a hypothalamic Na+,K+-ATPase inhibitor. Hypertension 1987; 9: 315-324
    CrossrefPubMedGoogle Scholar
  • 9 Goto A, Yamada K, Ishii M, Yoshioka M, Ishiguro T, Eguchi C, Sugimoto T. Purification and characterization of human urine-derived digitalis-like factor. Biochem Biophys Res Commun 1988; 154: 847-853
    CrossrefPubMedGoogle Scholar
  • 10 Goto A, Ishiguro T, Yamada K, Ishii M, Yoshioka M, Eguchi C, Shimora M, Sugimoto T. Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun 1990; 173: 1093-1101
    CrossrefPubMedGoogle Scholar
  • 11 Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 1991; 88: 6259-6263
    CrossrefPubMedGoogle Scholar
  • 12 Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM. Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 1991; 17: 944-950
    CrossrefPubMedGoogle Scholar
  • 13 Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30: 886-896
    CrossrefPubMedGoogle Scholar
  • 14 Buckalew VM. Endogenous digitalis-like factors: an overview of the history. Front Endocrinol (Lausanne) 2015; 6: 49
    PubMedGoogle Scholar
  • 15 Berendes E, Cullen P, Van Aken H, Zidek W, Erren M, Hübschen M, Weber T, Wirtz S, Tepel M, Walter M. Endogenous glycosides in critically ill patients. Crit Care Med 2003; 31: 1331-1337
    CrossrefPubMedGoogle Scholar
  • 16 Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878
    CrossrefPubMedGoogle Scholar
  • 17 Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, Agha SA, Rashad MA, Waheed S, Laskar S, Smith AL, Butler J. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2009; 2: 90-97
    CrossrefPubMedGoogle Scholar
  • 18 Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes 2013; 6: 525-533
    CrossrefPubMedGoogle Scholar
  • 19 Opie LH. Digitalis, yesterday and today, but not forever. Circ Cardiovasc Qual Outcomes 2013; 6: 511-513
    CrossrefPubMedGoogle Scholar
  • 20 Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015; 36: 1831-1838
    CrossrefPubMedGoogle Scholar
  • 21 Chaggar PS, Shaw SM, Williams SG. Is foxglove effective in heart failure?. Cardiovasc Ther 2015; 33: 236-241
    CrossrefPubMedGoogle Scholar
  • 22 Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351: h4451
    CrossrefPubMedGoogle Scholar
  • 23 Shiratori O. Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: in vitro and in vivo studies. Gan 1967; 58: 521-528
    PubMedGoogle Scholar
  • 24 Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S. Cardiac glycosides and breast cancer. Lancet 1979; 1: 563
    PubMedGoogle Scholar
  • 25 Slingerland M, Cerella C, Guchelaar HJ, Diederich M, Gelderblom H. Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. Invest New Drugs 2013; 31: 1087-1094
    CrossrefPubMedGoogle Scholar
  • 26 Alevizopoulos K, Calogeropoulou T, Lang F, Stournaras C. Na+/K+ ATPase inhibitors in cancer. Curr Drug Targets 2014; 15: 988-1000
    CrossrefPubMedGoogle Scholar
  • 27 Calderón-Montaño JM, Burgos-Morón E, Orta ML, Maldonado-Navas D, García-Domínguez I, López-Lázaro M. Evaluating the cancer therapeutic potential of cardiac glycosides. Biomed Res Int 2014; 2014: 794930
    PubMedGoogle Scholar
  • 28 Durlacher CT, Chow K, Chen XW, He ZX, Zhang X, Yang T, Zhou SF. Targeting Na(+)/K(+) -translocating adenosine triphosphatase in cancer treatment. Clin Exp Pharmacol Physiol 2015; 42: 427-443
    CrossrefPubMedGoogle Scholar
  • 29 Patel S. Plant-derived cardiac glycosides: Role in heart ailments and cancer management. Biomed Pharmacother 2016; 84: 1036-1041
    CrossrefPubMedGoogle Scholar
  • 30 Diederich M, Muller F, Cerella C. Cardiac glycosides: From molecular targets to immunogenic cell death. Biochem Pharmacol 2017; 125: 1-11
    CrossrefPubMedGoogle Scholar
  • 31 Lancaster MC, Vegad JL. Suppression of the early inflammatory response in the sheep by strophanthin G. Nature 1967; 213: 840-841
    PubMedGoogle Scholar
  • 32 De Vasconcelos DI, Leite JA, Carneiro LT, Piuvezam MR, de Lima MR, de Morais LC, Rumjanek VM, Rodrigues-Mascarenhas S. Anti-inflammatory and antinociceptive activity of ouabain in mice. Mediators Inflamm 2011; 2011: 912925
    PubMedGoogle Scholar
  • 33 Leite JA, Alves AK, Galvão JG, Teixeira MP, Cavalcante-Silva LH, Scavone C, Morrot A, Rumjanek VM, Rodrigues-Mascarenhas S. Ouabain modulates zymosan-induced peritonitis in mice. Mediators Inflamm 2015; 2015: 265798
    PubMedGoogle Scholar
  • 34 Esposito AL. Digoxin disrupts the inflammatory response in experimental pneumococcal pneumonia. J Infect Dis 1985; 152: 14-23
    CrossrefPubMedGoogle Scholar
  • 35 Jacob PL, Leite JA, Alves AK, Rodrigues YK, Amorim FM, Neris PL, Oliveira MR, Rodrigues-Mascarenhas S. Immunomodulatory activity of ouabain in Leishmania leishmania amazonensis-infected Swiss mice. Parasitol Res 2013; 112: 1313-1321
    CrossrefPubMedGoogle Scholar
  • 36 Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011; 472: 486-490
    CrossrefPubMedGoogle Scholar
  • 37 Lee J, Baek S, Lee J, Lee J, Lee DG, Park MK, Cho ML, Park SH, Kwok SK. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Int Immunopharmacol 2015; 26: 103-111
    CrossrefPubMedGoogle Scholar
  • 38 Hinshaw SJ, Ogbeifun O, Wandu WS, Lyu C, Shi G, Li Y, Qian H, Gery I. Digoxin inhibits induction of experimental autoimmune uveitis in mice, but causes severe retinal degeneration. Invest Ophthalmol Vis Sci 2016; 57: 1441-1447
    CrossrefPubMedGoogle Scholar
  • 39 Forshammar J, Block L, Lundborg C, Biber B, Hansson E. Naloxone and ouabain in ultralow concentrations restore Na+/K+-ATPase and cytoskeleton in lipopolysaccharide-treated astrocytes. J Biol Chem 2011; 286: 31586-31597
    CrossrefPubMedGoogle Scholar
  • 40 Forshammar J, Jörneberg P, Björklund U, Westerlund A, Lundborg C, Biber B, Hansson E. Anti-inflammatory substances can influence some glial cell types but not others. Brain Res 2013; 1539: 34-40
    CrossrefPubMedGoogle Scholar
  • 41 Kinoshita PF, Yshii LM, Vasconcelos AR, Orellana AM, Lima Lde S, Davel AP, Rossoni LV, Kawamoto EM, Scavone C. Signaling function of Na,K-ATPase induced by ouabain against LPS as an inflammation model in hippocampus. J Neuroinflammation 2014; 11: 218
    CrossrefPubMedGoogle Scholar
  • 42 Srivastava M, Eidelman O, Zhang J, Paweletz C, Caohuy H, Yang Q, Jacobson KA, Heldman E, Huang W, Jozwik C, Pollard BS, Pollard HB. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A 2004; 101: 7693-7698
    CrossrefPubMedGoogle Scholar
  • 43 Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, Srivastava M, Esposito D, Gillette W, Hartley J, Pollard HB. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci U S A 2005; 102: 9631-9636
    CrossrefPubMedGoogle Scholar
  • 44 Zeitlin PL, Diener-West M, Callahan KA, Lee S, Talbot jr. CC, Pollard B, Boyle MP, Lechtzin N. Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding. Ann Am Thorac Soc 2017; 14: 220-229
    CrossrefPubMedGoogle Scholar
  • 45 Quastel MR, Kaplan JG. Inhibition by ouabain of human lymphocyte transformation induced by phytohaemagglutinin in vitro . Nature 1968; 219: 198-200
    CrossrefPubMedGoogle Scholar
  • 46 Quastel MR, Kaplan JG. Lymphocyte stimulation: the effect of ouabain on nucleic acid and protein synthesis. Exp Cell Res 1970; 62: 407-420
    CrossrefPubMedGoogle Scholar
  • 47 Takada Y, Matsuo K, Ogura H, Bai L, Toki A, Wang L, Ando M, Kataoka T. Odoroside A and ouabain inhibit Na+/K+-ATPase and prevent NF-kappaB-inducible protein expression by blocking Na+-dependent amino acid transport. Biochem Pharmacol 2009; 78: 1157-1166
    CrossrefPubMedGoogle Scholar
  • 48 Szamel M, Somogyi J, Csukás I, Solymosy F. Effect of ouabain on macromolecular synthesis during the cell cycle in mitogen-stimulated human lymphocytes. Biochim Biophys Acta 1980; 633: 347-360
    CrossrefPubMedGoogle Scholar
  • 49 Szamel M, Resch K. Inhibition of lymphocyte activation by ouabain. Interference with the early activation of membrane phospholipid metabolism. Biochim Biophys Acta 1981; 647: 297-301
    CrossrefPubMedGoogle Scholar
  • 50 Pires V, Harab RC, Olej B, Rumjanek VM. Ouabain effects on activated lymphocytes: augmentation of CD25 expression on TPA-stimulated cells and of CD69 on PHA-and TPA-stimulated cells. Int J Immunopharmacol 1997; 19: 143-148
    CrossrefPubMedGoogle Scholar
  • 51 Stoeck M, Northoff H, Resch K. Inhibition of mitogen-induced lymphocyte proliferation by ouabain: interference with interleukin 2 production and interleukin 2 action. J Immunol 1983; 131: 1433-1437
    PubMedGoogle Scholar
  • 52 Lillehoj H, Shevach EM. A comparison of the effects of cyclosporin A, dexamethasone, and ouabain on the interleukin-2 cascade. J Immunopharmacol 1985; 7: 267-284
    CrossrefPubMedGoogle Scholar
  • 53 Dornand J, Favero J, Bonnafous JC, Mani JC. Mechanism whereby ouabain inhibits human T lymphocyte activation: effect on the interleukin 2 pathway. Immunobiology 1986; 171: 436-450
    CrossrefPubMedGoogle Scholar
  • 54 Falciola J, Volet B, Anner RM, Moosmayer M, Lacotte D, Anner BM. Role of cell membrane Na,K-ATPase for survival of human lymphocytes in vitro . Biosci Rep 1994; 14: 189-204
    CrossrefPubMedGoogle Scholar
  • 55 Szamel M, Schneider S, Resch K. Functional interrelationship between (Na+ + K+)-ATPase and lysolecithin acyltransferase in plasma membranes of mitogen-stimulated rabbit thymocytes. J Biol Chem 1981; 256: 9198-9204
    PubMedGoogle Scholar
  • 56 Rodrigues-Mascarenhas S, Bloise FF, Moscat J, Rumjanek VM. Ouabain inhibits p38 activation in thymocytes. Cell Biol Int 2008; 32: 1323-1328
    CrossrefPubMedGoogle Scholar
  • 57 Rodrigues-Mascarenhas S, Echevarria-Lima J, Fernandes dos Santos N, Rumjanek VM. CD69 expression induced by thapsigargin, phorbol ester and ouabain on thymocytes is dependent on external Ca2+ entry. Life Sci 2003; 73: 1037-1051
    CrossrefPubMedGoogle Scholar
  • 58 Mann CL, Bortner CD, Jewell CM, Cidlowski JA. Glucocorticoid-induced plasma membrane depolarization during thymocyte apoptosis: association with cell shrinkage and degradation of the Na(+)/K(+)-adenosine triphosphatase. Endocrinology 2001; 142: 5059-5068
    CrossrefPubMedGoogle Scholar
  • 59 Rodrigues-Mascarenhas S, dos Santos NF, Rumjanek VM. Synergistic effect between ouabain and glucocorticoids for the induction of thymic atrophy. Biosci Rep 2006; 26: 159-169
    CrossrefPubMedGoogle Scholar
  • 60 Milthorp P, Quastel MR, Kaplan JG, Vogelfanger IJ. Effect of the inhibition of cation transport by ouabain on plaque formation by splenic lymphoid cells: time course and dose response. Cell Immunol 1974; 14: 128-133
    CrossrefPubMedGoogle Scholar
  • 61 Maubach K, Foey AD, Hall ND. Impaired activity of thiol-dependent ATPases in rheumatoid mononuclear cell membranes. Agents Actions 1993; 39 (Spec No): C107-C109
    CrossrefPubMedGoogle Scholar
  • 62 Foey AD, Crawford A, Hall ND. Modulation of cytokine production by human mononuclear cells following impairment of Na, K-ATPase activity. Biochim Biophys Acta 1997; 1355: 43-49
    CrossrefPubMedGoogle Scholar
  • 63 Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Iwasaki A, Nose Y, Sasayama S. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997; 96: 1501-1506
    CrossrefPubMedGoogle Scholar
  • 64 Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000; 12: 294-297
    CrossrefPubMedGoogle Scholar
  • 65 Ihenetu K, Espinosa R, de Leon R, Planas G, Perez-Pinero A, Waldbeser L. Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. Inflamm Res 2008; 57: 519-523
    CrossrefPubMedGoogle Scholar
  • 66 Sowa G, Przewłocki R. Ouabain enhances the lipopolysaccharide-induced nitric oxide production by rat peritoneal macrophages. Immunopharmacology 1997; 36: 95-100
    CrossrefPubMedGoogle Scholar
  • 67 Valente RC, Nascimento CR, Araujo EG, Rumjanek VM. mCD14 expression in human monocytes is downregulated by ouabain via transactivation of epithelial growth factor receptor and activation of p38 mitogen-activated protein kinase. Neuroimmunomodulation 2009; 16: 228-236
    CrossrefPubMedGoogle Scholar
  • 68 Teixeira MP, Rumjanek VM. Ouabain affects the expression of activation markers, cytokine production, and endocytosis of human monocytes. Mediators Inflamm 2014; 2014: 760368
    PubMedGoogle Scholar
  • 69 Ward PA, Becker EL. Potassium reversible inhibition of leukotaxis by ouabain. Life Sci 1970; 9: 355-360
    CrossrefPubMedGoogle Scholar
  • 70 De Moraes VL, Olej B, de la Rocque L, Rumjanek VM. Lack of sensitivity to ouabain in natural killer activity. FASEB J 1989; 3: 2425-2429
    CrossrefPubMedGoogle Scholar
  • 71 Nascimento CR, Valente RC, Echevarria-Lima J, Fontes CF, de Araujo-Martins L, Araujo EG, Rumjanek VM. The influence of ouabain on human dendritic cells maturation. Mediators Inflamm 2014; 2014: 494956
    PubMedGoogle Scholar
  • 72 Bereta J, Cohen MC, Bereta M. Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-kappa B. FEBS Lett 1995; 377: 21-25
    CrossrefPubMedGoogle Scholar
  • 73 Jagielska J, Salguero G, Schieffer B, Bavendiek U. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?. Atherosclerosis 2009; 206: 390-396
    CrossrefPubMedGoogle Scholar
  • 74 Goto A, Yamada K, Nagoshi H, Terano Y, Omata M. Stress-induced elevation of ouabainlike compound in rat plasma and adrenal. Hypertension 1995; 26: 1173-1176
    CrossrefPubMedGoogle Scholar
  • 75 Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992; 86: 420-425
    CrossrefPubMedGoogle Scholar